 |
|
|
| |
Population PK and Exposure-Response Analysis of Orally Administered VH4011499 in People With HIV-1
|
| |
| |
CROI 2026 Feb 22-26 Denver
Nilay Thakkar,1 Kenny Watson,2 Rulan Griesel,3 Amy Pierce,4 Jacob E. Robinson,4 Jerry L. Jeffrey,4 Konstantinos Angelis,5 Paul Benn,3 Yash Gandhi1
1GSK, Collegeville, PA, USA; 2Certara Strategic Consulting, Sheffield, UK; 3ViiV Healthcare, London, UK; 4ViiV Healthcare, Durham, NC, USA; 5GSK, London, UK
Acknowledgments: This study was funded by ViiV Healthcare. The authors would like to thank the study participants, the investigators and site staff, and the ViiV Healthcare and GSK study team members. Editorial assistance and graphic design support for this poster were provided under the direction of the authors by Fingerpaint Medical and funded by ViiV Healthcare.
|
| |
|
|
|
|
|
